[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601519":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":40,"centralContacts":45,"locations":51,"responsibleParty":153,"collaborators":155,"id":158,"slug":159,"hasResults":160,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":49,"eligibilityCriteria":164,"healthyVolunteers":160,"sex":165,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":49,"studyType":171,"phases":172,"briefSummary":174,"conditions":175,"keywords":49,"overallStatus":72,"whyStopped":49,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"Nanjing Leads Biolabs Co.,Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LBL-024+Gemcitabine Hydrochloride+Cisplatin\u002FLBL-024+Bevacizumab","EXPERIMENTAL","Cohort 1：\n\nSubjects were treated with LBL-024 combined with gemcitabine and cisplatin\n\nCohort 2：\n\nSubjects were treated with LBL-024 combined with Bevacizumab.\n\nIntravenous infusion.",[13,14,15,16],"Drug: LBL-024 for Injection","Drug: Cisplatin Injection","Drug: Gemcitabine Hydrochloride for Injection","Drug: Bevacizumab Injection",[18,25,30,35],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","LBL-024 for Injection","Intravenous infusion.",[9],[24],"LBL-024",{"type":19,"name":26,"description":21,"armGroupLabels":27,"otherNames":28},"Cisplatin Injection",[9],[29],"Cisplatin",{"type":19,"name":31,"description":21,"armGroupLabels":32,"otherNames":33},"Gemcitabine Hydrochloride for Injection",[9],[34],"Gemcitabine Hydrochloride",{"type":19,"name":36,"description":21,"armGroupLabels":37,"otherNames":38},"Bevacizumab Injection",[9],[39],"Bevacizumab",[41],{"name":42,"affiliation":43,"role":44},"Jian zhou","Shanghai Zhongshan Hospital","PRINCIPAL_INVESTIGATOR",[46],{"name":42,"role":47,"phone":48,"phoneExt":49,"email":50},"CONTACT","021-64041990",null,"maxy@leadsbiolabs.com",[52,70,84,96,108,120,132,144],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"The First Affiliated Hospital of Guangxi Medical University","NOT_YET_RECRUITING","Nanning","Guangxi","530021","China","CN",{"type":61,"coordinates":62},"Point",[63,64],108.31667,22.81667,{"lat":64,"lon":63},[67],{"name":68,"role":47,"phone":69,"phoneExt":49,"email":50},"xiangyu Ma","02583378099",{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":58,"countryCode":59,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Henan Cancer Hospital","RECRUITING","Zhengzhou","Henan","450008",{"type":61,"coordinates":77},[78,79],113.64861,34.75778,{"lat":79,"lon":78},[82],{"name":68,"role":47,"phone":83,"phoneExt":49,"email":50},"025-83378099",{"facility":85,"status":72,"city":86,"state":87,"zip":88,"country":58,"countryCode":59,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Xiangyang Central Hospital","Xiangyang","Hubei","441106",{"type":61,"coordinates":90},[91,92],112.14479,32.0422,{"lat":92,"lon":91},[95],{"name":68,"role":47,"phone":83,"phoneExt":49,"email":50},{"facility":97,"status":72,"city":98,"state":99,"zip":100,"country":58,"countryCode":59,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Jiangxi Cancer Hospital","Nanchang","Jiangxi","330029",{"type":61,"coordinates":102},[103,104],115.85306,28.68396,{"lat":104,"lon":103},[107],{"name":68,"role":47,"phone":83,"phoneExt":49,"email":50},{"facility":109,"status":54,"city":110,"state":111,"zip":112,"country":58,"countryCode":59,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Shandong Cancer Hospital","Jinan","Shandong","250117",{"type":61,"coordinates":114},[115,116],116.99722,36.66833,{"lat":116,"lon":115},[119],{"name":68,"role":47,"phone":69,"phoneExt":49,"email":50},{"facility":121,"status":72,"city":122,"state":123,"zip":124,"country":58,"countryCode":59,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Zhongshan Hospital of Fudan University","Shanghai","Shanghai Municipality","200032",{"type":61,"coordinates":126},[127,128],121.45806,31.22222,{"lat":128,"lon":127},[131],{"name":68,"role":47,"phone":83,"phoneExt":49,"email":50},{"facility":133,"status":72,"city":134,"state":135,"zip":136,"country":58,"countryCode":59,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine","Hangzhou","Zhejiang","310016",{"type":61,"coordinates":138},[139,140],120.16142,30.29365,{"lat":140,"lon":139},[143],{"name":68,"role":47,"phone":83,"phoneExt":49,"email":50},{"facility":145,"status":72,"city":134,"state":135,"zip":146,"country":58,"countryCode":59,"cosmosGeoPoint":147,"geoPoint":149,"contacts":150},"Zhejiang Cancer Hospital","310022",{"type":61,"coordinates":148},[139,140],{"lat":140,"lon":139},[151],{"name":152,"role":47,"phone":83,"phoneExt":49,"email":50},"Xiangyu Ma",{"type":154,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR",[156],{"name":43,"class":157},"OTHER","100601519","phase-2-a-clinical-trial-of-lbl-024-combination-drug-in-patients-with-advanced-solid-tumourssubstudy-02btchcc-100601519",false,"NCT07111546","A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 02(BTC&HCC)]","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. Age 18-75 years (inclusive of boundaries) at the time of signing informed consent form.\n3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have at least one measurable lesion.\n6. There is adequate organ and bone marrow function,Conforms to laboratory test results.\n7. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.\n\nExclusion Criteria:\n\n1. Participation in clinical studies of antineoplastic agents within 4 weeks before the first use of study drug,or Subject is expected to receive any other form of systemic or local anti-tumor therapy outside the protocol during the study.\n2. Use of immunomodulatory drugs within 2 weeks before the first use of study drug,Including but not limited to thymopeptide, interleukins, interferon, etc.\n3. Patients with active infection and requiring intravenous anti-infective therapy within 2 weeks before the first dose.\n4. Patients with clinically uncontrollable pleural effusion, pericardial effusion, ascites, and those requiring repeated drainage or medical intervention.\n5. The patient has a Medical history of immunodeficiency, including HIV antibody positive.\n6. Women during pregnancy or lactation.\n7. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism or drug addiction.\n8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.","ALL","18 Years","75 Years",{"count":169,"type":170},140,"ESTIMATED","INTERVENTIONAL",[173],"PHASE2","An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.",[176],"Advanced Solid Tumour","2026-05-22",{"date":179,"type":180},"2026-05-26","ACTUAL",{"date":182,"type":180},"2025-10-20",{"date":184,"type":170},"2027-12-26",{"name":5,"class":6},8]